Stock Is Falling Today - Here's Why
Novavax Inc NVAX faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine. This delay comes at a challenging time for the US-listed biotech, grappling with declining demand for COVID-19 vaccines. The EMA was set to approve the updated jab,…
#novavaxincnvax #ema #novavax #fda #bntx #pfizerincpfe #modernainc #nvax
